The Role of MicroRNA-155 As a Biomarker in Diffuse Large B-Cell Lymphoma

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2025 Jan 8

PMID 39767565

Authors

Epameinondas Koumpis

Vasileios Georgoulis

Konstantina Papathanasiou

Alexandra Papoudou-Bai

Panagiotis Kanavaros

Evangelos Kolettas

Eleftheria Hatzimichael

Affiliations

Soon will be listed here.

Abstract

Diffuse Large B-cell Lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL). Despite the use of newer agents, such as polatuzumab vedotin, more than one-third of patients have ultimately relapsed or experienced refractory disease. MiRNAs are single-stranded, ~22-nucleotide-long RNAs that interact with their target RNA. They are significant regulators of post-transcriptional gene expression. One significant miRNA, miR-155, is involved in the pathophysiology of DLBCL and it is a critical modulator of hematopoiesis, inflammation, and immune responses. Targets of miR-155, such as histone deacetylase 4 (HDAC4), suppressor of cytokine signaling-1 (SOCS1) and immune cells, play a crucial role in DLBCL pathogenesis, since miR-155 regulates key pathways, transcription factors and cytokine expression and shapes the tumor microenvironment in DLBCL. In this review, we examine the role of miR-155 in DLBCL and its potential as a future diagnostic, prognostic, or predictive biomarker.

References

Cui B, Chen L, Zhang S, Mraz M, Fecteau J, Yu J . MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014; 124(4):546-54. PMC: 4110661. DOI: 10.1182/blood-2014-03-559690. View

Wightman B, Ha I, Ruvkun G . Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993; 75(5):855-62. DOI: 10.1016/0092-8674(93)90530-4. View

Grimaldi A, Nuzzo S, Condorelli G, Salvatore M, Incoronato M . Prognostic and Clinicopathological Significance of MiR-155 in Breast Cancer: A Systematic Review. Int J Mol Sci. 2020; 21(16). PMC: 7461504. DOI: 10.3390/ijms21165834. View

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

Vigorito E, Perks K, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S . microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007; 27(6):847-59. PMC: 4135426. DOI: 10.1016/j.immuni.2007.10.009. View

Costinean S, Sandhu S, Pedersen I, Tili E, Trotta R, Perrotti D . Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood. 2009; 114(7):1374-82. PMC: 2727407. DOI: 10.1182/blood-2009-05-220814. View

Li Y, Zhang L, Dong Z, Xu H, Yan L, Wang W . MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer. Pathol Res Pract. 2021; 220:153405. DOI: 10.1016/j.prp.2021.153405. View

Zhong H, Xu L, Zhong J, Xiao F, Liu Q, Huang H . Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma. Exp Ther Med. 2012; 3(5):763-770. PMC: 3438582. DOI: 10.3892/etm.2012.502. View

Lawrie C, Chi J, Taylor S, Tramonti D, Ballabio E, Palazzo S . Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med. 2009; 13(7):1248-60. PMC: 4496139. DOI: 10.1111/j.1582-4934.2008.00628.x. View

10.

Sur D, Advani S, Braithwaite D . MicroRNA panels as diagnostic biomarkers for colorectal cancer: A systematic review and meta-analysis. Front Med (Lausanne). 2022; 9:915226. PMC: 9676370. DOI: 10.3389/fmed.2022.915226. View

11.

Ferrajoli A, Shanafelt T, Ivan C, Shimizu M, Rabe K, Nouraee N . Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013; 122(11):1891-9. PMC: 3779381. DOI: 10.1182/blood-2013-01-478222. View

12.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

13.

Culpin R, Sieniawski M, Angus B, Menon G, Proctor S, Milne P . Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients. Histopathology. 2013; 63(6):788-801. DOI: 10.1111/his.12223. View

14.

Eis P, Tam W, Sun L, Chadburn A, Li Z, Gomez M . Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005; 102(10):3627-32. PMC: 552785. DOI: 10.1073/pnas.0500613102. View

15.

Fang C, Zhu D, Dong H, Zhou Z, Wang Y, Liu L . Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol. 2011; 91(4):553-9. DOI: 10.1007/s00277-011-1350-9. View

16.

Lone S, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S . Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022; 21(1):79. PMC: 8932066. DOI: 10.1186/s12943-022-01543-7. View

17.

Muringampurath-John D, Jaye D, Flowers C, Saxe D, Chen Z, Lechowicz M . Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. Br J Haematol. 2012; 158(5):608-14. DOI: 10.1111/j.1365-2141.2012.09209.x. View

18.

Mann M, Mehta A, Zhao J, Lee K, Marinov G, Garcia-Flores Y . An NF-κB-microRNA regulatory network tunes macrophage inflammatory responses. Nat Commun. 2017; 8(1):851. PMC: 5636846. DOI: 10.1038/s41467-017-00972-z. View

19.

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

20.

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View